# A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia

> **NCT07251309** · PHASE3 · RECRUITING · sponsor: **Waterstone Pharmaceutical (Wuhan) Co., LTD.** · enrollment: 420 (estimated)

## Conditions studied

- Hyperkalemia

## Interventions

- **DRUG:** WS016
- **DRUG:** Placebo
- **DRUG:** WS016
- **DRUG:** Placebo
- **DRUG:** WS016

## Key facts

- **NCT ID:** NCT07251309
- **Lead sponsor:** Waterstone Pharmaceutical (Wuhan) Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-23
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07251309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07251309, "A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07251309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*